Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The effects of lactoferrin in a rat model of catecholamine cardiotoxicity

P. Mladěnka, V. Semecký, Z. Bobrovová, P. Nachtigal, J. Vávrová, M. Holečková, V. Palička, Y. Mazurová, R. Hrdina

. 2009 ; 22 (2) : 353-361.

Jazyk angličtina Země Nizozemsko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc11017322

E-zdroje NLK

ProQuest Central od 1997-03-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-03-01 do Před 1 rokem

Lactoferrin is recently under intense investigation because of its proposed several pharmacologically positive effects. Based on its iron-binding properties and its physiological presence in the human body, it may have a significant impact on pathological conditions associated with iron-catalysed reactive oxygen species (ROS). Its effect on a catecholamine model of myocardial injury, which shares several pathophysiological features with acute myocardial infarction (AMI) in humans, was examined. Male Wistar rats were randomly divided into four groups according to the received medication: control (saline), isoprenaline (ISO, 100 mg kg(-1) s.c.), bovine lactoferrin (La, 50 mg kg(-1) i.v.) or a combination of La + ISO in the above-mentioned doses. After 24 h, haemodynamic functional parameters were measured, a sample of blood was withdrawn and the heart was removed for analysis of various parameters. Lactoferrin premedication reduced some impairment caused by ISO (e.g. a stroke volume decrease, an increase in peripheral resistance and calcium overload). These positive effects were likely to have been mediated by the positive inotropic effect of lactoferrin and by inhibition of ROS formation due to chelation of free iron. The failure of lactoferrin to provide higher protection seems to be associated with the complexity of catecholamine cardiotoxicity and with its hydrophilic character.

000      
03148naa 2200481 a 4500
001      
bmc11017322
003      
CZ-PrNML
005      
20121127121001.0
008      
110629s2009 ne e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Mladěnka, Přemysl. $7 xx0233006
245    14
$a The effects of lactoferrin in a rat model of catecholamine cardiotoxicity / $c P. Mladěnka, V. Semecký, Z. Bobrovová, P. Nachtigal, J. Vávrová, M. Holečková, V. Palička, Y. Mazurová, R. Hrdina
314    __
$a Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Charles University in Prague, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic. mladenkap@faf.cuni.cz
520    9_
$a Lactoferrin is recently under intense investigation because of its proposed several pharmacologically positive effects. Based on its iron-binding properties and its physiological presence in the human body, it may have a significant impact on pathological conditions associated with iron-catalysed reactive oxygen species (ROS). Its effect on a catecholamine model of myocardial injury, which shares several pathophysiological features with acute myocardial infarction (AMI) in humans, was examined. Male Wistar rats were randomly divided into four groups according to the received medication: control (saline), isoprenaline (ISO, 100 mg kg(-1) s.c.), bovine lactoferrin (La, 50 mg kg(-1) i.v.) or a combination of La + ISO in the above-mentioned doses. After 24 h, haemodynamic functional parameters were measured, a sample of blood was withdrawn and the heart was removed for analysis of various parameters. Lactoferrin premedication reduced some impairment caused by ISO (e.g. a stroke volume decrease, an increase in peripheral resistance and calcium overload). These positive effects were likely to have been mediated by the positive inotropic effect of lactoferrin and by inhibition of ROS formation due to chelation of free iron. The failure of lactoferrin to provide higher protection seems to be associated with the complexity of catecholamine cardiotoxicity and with its hydrophilic character.
590    __
$a bohemika - dle Pubmed
650    _2
$a zvířata $7 D000818
650    _2
$a katecholaminy $x metabolismus $7 D002395
650    _2
$a skot $7 D002417
650    _2
$a chelátory $x farmakologie $7 D002614
650    _2
$a glutathion $x metabolismus $7 D005978
650    _2
$a glutathionperoxidasa $x metabolismus $7 D005979
650    _2
$a hemodynamika $7 D006439
650    _2
$a železo $x chemie $7 D007501
650    _2
$a laktoferrin $x chemie $7 D007781
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a infarkt myokardu $x metabolismus $7 D009203
650    _2
$a pilotní projekty $7 D010865
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a reaktivní formy kyslíku $7 D017382
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Semecký, Vladimír, $d 1943- $7 nlk19990073843
700    1_
$a Bobrovová, Zuzana $7 xx0106425
700    1_
$a Nachtigal, Petr $7 uk2009304471
700    1_
$a Vávrová, Jaroslava, $d 1958- $7 xx0014618
700    1_
$a Holečková, Magdalena $7 xx0074146
700    1_
$a Palička, Vladimír, $d 1946- $7 jn99240000830
700    1_
$a Mazurová, Yvona, $d 1951- $7 xx0054511
700    1_
$a Hrdina, Radomír $7 xx0077249
773    0_
$t BioMetals $w MED00007558 $g Roč. 22, č. 2 (2009), s. 353-361
910    __
$a ABA008 $b x $y 2
990    __
$a 20110720112731 $b ABA008
991    __
$a 20121127121027 $b ABA008
999    __
$a ok $b bmc $g 864234 $s 727131
BAS    __
$a 3
BMC    __
$a 2009 $x MED00007558 $b 22 $c 2 $d 353-361 $m BioMetals $n Biometals
LZP    __
$a 2011-3B09/BBjvme